Tammewar A M, Cheng L, Kayikcioglu O R, Falkenstein I A, Kozak I, Goldbaum M H, Freeman W R
Joan and Irwin Jacobs Retina Center, Shiley Eye Center, UCSD Department of Ophthalmology, La Jolla, CA 92037, USA.
Br J Ophthalmol. 2008 Jun;92(6):810-3. doi: 10.1136/bjo.2007.126227. Epub 2008 Apr 17.
To compare the non-decanted (standard) 4 mg versus the decanted 20 mg intravitreal triamcinolone acetonide (IVTA) injections and to assess their effect on intraocular pressure (IOP).
We retrospectively reviewed the records of 92 consecutive eyes, which received an intravitreal injection of either dose of triamcinolone acetonide, at a single retina centre. The change in IOP (elevation of at least 5 mm Hg from baseline or above 21 mm Hg) was analysed with a multivariate logistic analysis. The mean follow-up period in both groups was 27 weeks. A subgroup analysis comparing vitrectomised to non-vitrectomised eyes in both groups was also performed.
Of the 92 eyes, 46% (23 of 51) in the 4 mg group versus 30% (12 of 41) in the 20 mg group had an IOP >21 mm of Hg (p = 0.14) after a mean follow-up period of 27 weeks. The vitrectomised eyes (3 of 24) in the 20 mg group had a significantly lower rate of IVTA induced IOP elevation than the non-vitrectomised eyes (9 of 17) (p = 0.013). The IOP elevation occurred significantly earlier in the 4 mg group (vitrectomised eyes 27 (SD 43) days and non-vitrectomised eyes 61 (52) days) than in the 20 mg group (vitrectomised eyes 104 (56) days and non-vitrectomised eyes 119 (82) days), independent of the vitreous status (vitrectomised p = 0.05 and non-vitrectomised p = 0.04). The mean value of initial high IOP in the non-vitrectomised eyes was higher in the 4 mg group than in the corresponding 20 mg group (p = 0.048).
Decanted 20 mg IVTA may not pose a significantly greater risk of IOP elevation than the 4 mg non-decanted IVTA.
比较未倾析(标准)4毫克与倾析20毫克玻璃体内注射曲安奈德(IVTA),并评估它们对眼压(IOP)的影响。
我们回顾性分析了在单一视网膜中心接受任一剂量曲安奈德玻璃体内注射的92只连续眼睛的记录。采用多因素逻辑分析评估眼压变化(相对于基线至少升高5毫米汞柱或高于21毫米汞柱)。两组的平均随访期均为27周。还对两组中接受玻璃体切割术的眼睛与未接受玻璃体切割术的眼睛进行了亚组分析。
92只眼中,4毫克组46%(51只中的23只),20毫克组30%(41只中的12只)在平均27周的随访期后眼压>21毫米汞柱(p = 0.14)。20毫克组中接受玻璃体切割术的眼睛(24只中的3只)IVTA引起眼压升高的发生率显著低于未接受玻璃体切割术的眼睛(17只中的9只)(p = 0.013)。4毫克组眼压升高出现的时间显著早于20毫克组(接受玻璃体切割术的眼睛为27(标准差43)天,未接受玻璃体切割术的眼睛为61(52)天),而20毫克组分别为104(56)天和119(82)天,与玻璃体状态无关(接受玻璃体切割术的眼睛p = 0.05,未接受玻璃体切割术的眼睛p = 0.04)。未接受玻璃体切割术的眼睛中,4毫克组初始高眼压的平均值高于相应的20毫克组(p = 0.048)。
倾析20毫克IVTA引起眼压升高的风险可能并不显著高于未倾析的4毫克IVTA。